XML 31 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
Commitments and Contingencies (Details Textual) - USD ($)
 2 Months Ended 6 Months Ended
May 06, 2016
Sep. 30, 2015
Mar. 31, 2016
Mar. 30, 2016
Dec. 29, 2015
Commitments and Contingencies (Textual)          
Amount received from BriVision   $ 22,517   $ 10,000,000  
Common stock newly issued, shares   6,650,957 2,031,423    
Collaborative Agreement [Member]          
Commitments and Contingencies (Textual)          
Description of payment settlement schedule    
 ● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.
   
  upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.
   
 ●upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.
   
 ●at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.
   
 ●upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
    
Amount received from BriVision         $ 100,000,000
Upfront payments     $ 3,500,000    
Percentage of payments under collaborative agreement     3.50%    
Licensing rights     $ 3,500,000    
Collaborative Agreement [Member] | Subsequent Event [Member]          
Commitments and Contingencies (Textual)          
Milestone payments to BioLite in cash $ 2,600,000        
Common stock newly issued, value $ 900,000        
Common stock newly issued, shares 562,500        
Share price $ 1.60        
Collaborative Agreement One [Member]          
Commitments and Contingencies (Textual)          
Percentage of payments under collaborative agreement     6.50%    
Accounts payable     $ 6,500,000